Eli Lilly and Company (LLY) announced that the U.S. Nuclear Regulatory Commission has issued its consent for the indirect transfer of control of Point Biopharma Global’s (PNT) radioactive materials license, which will occur following the completion of Lilly’s previously announced tender offer to acquire all of the issued and outstanding shares of common stock of POINT, for a purchase price of $12.50 per share in cash, without interest and less any applicable tax withholding. Obtaining the NRC Consent is the last regulatory approval necessary for the consummation of the transaction. The tender offer is scheduled to expire at 5:00 p.m., Eastern time, on Nov. 16, 2023, unless the tender offer is further extended or earlier terminated.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma
- Eli Lilly (NYSE:LLY) Slips despite Good News on Heart Drug
- ‘Hold Your Horses,’ Says Goldman Sachs About Eli Lilly Stock
- Deutsche says SELECT results may be dampened by Novo’s Medicare comments
- Novo Nordisk data positive for Eli Lilly shares, says JPMorgan